Ft839

Preclinical

FFate Therapeutics

Ft839 is one of 6 therapeutic programs targeting ANCA Associated Vasculitis (AAV). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ANCA Associated Vasculitis (AAV)Recruiting

ANCA Associated Vasculitis (AAV)Preclinical

Recruiting

Competition

Competitive Landscape

5 competitors in ANCA Associated Vasculitis (AAV)

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 3

Imuran

LLegacy Health System

Phase 3

1 4

Rapcabtagene Autoleucel

Novartis

Phase 2

1 5

Glucocorticoids

Novartis

Phase 2

1 6

Ft839

FFate Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2040

PreclinicalRecruiting

ANCA Associated Vasculitis (AAV)

NCT07800871

Clinical

Trials by Indication[1]

ANCA Associated Vasculitis (AAV)1 trial

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

Recruiting·FFate Therapeutics·Preclinical·NCT07800871·446 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ft839. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ft839. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fate Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: FFate Therapeutics

Ft839

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2040

Trials by Indication[1]

ANCA Associated Vasculitis (AAV)1 trial

References

Drug Info

Quick Facts

Related News